Skip to main content
Medical information Clinical review pending

Genetic Testing

Oncopro Comprehensive Cancer Panel 161 Genes Test

The Oncopro Comprehensive Cancer Panel 161 Genes Test analyzes 161 genes linked to various cancers, aiding oncologists in developing personalized treatment strategies based on genetic mutations. Confirm with the laboratory before booking.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Formalin-fixed paraffin-embedded (FFPE) tissue block. The block should contain at least 10% tumor tissue.
Results
Reports are typically available within 35 working days after sample receipt. Confirm with the laboratory before booking.
Preparation
Ensure the submitted FFPE tissue block contains at least 10% tumor tissue. Confirm specific sample requirements with the laboratory before collection.
Test priceKSh 98,280

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Oncopro Comprehensive Cancer Panel 161 Genes Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with a personal or family history of cancer.
  • ✓Patients diagnosed with cancer seeking personalized treatment options.
  • ✓Patients whose cancer may have progressed despite standard treatment.
  • ✓Individuals with unexplained symptoms suggestive of cancer.
  • ✓Patients considering clinical trials based on genetic profile.
02

In plain language

What this test helps you understand

This test helps identify specific genetic mutations and alterations in cancer-related genes. This information can guide oncologists in selecting targeted therapies, predicting treatment response, and understanding cancer progression. It supports personalized medicine approaches.
The Oncopro Comprehensive Cancer Panel 161 Genes Test is an advanced diagnostic tool providing comprehensive insights into genetic factors associated with cancer. This test analyzes 161 genes, including hotspot genes, full-length genes, and evaluates copy number variations and fusions. It is a valuable resource for oncologists in tailoring personalized treatment plans.

This test detects genetic mutations and alterations that may contribute to cancer development and progression. By examining the specified genes, the Oncopro test provides information that can assist in identifying effective treatment options.

Results from the Oncopro Comprehensive Cancer Panel provide insights into the presence of specific genetic mutations. A genetic counselor or oncologist can help interpret these results and discuss potential next steps.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationEnsure the submitted FFPE tissue block contains at least 10% tumor tissue. Confirm specific sample requirements with the laboratory before collection.
SampleFormalin-fixed paraffin-embedded (FFPE) tissue block. The block should contain at least 10% tumor tissue.
MethodologyNext-Generation Sequencing (NGS) is used to analyze the 161 genes for mutations, copy number variations, and fusions.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes a specific panel of genes. It may not detect all possible genetic alterations associated with cancer. Results should be interpreted in the context of clinical findings and other diagnostic tests. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This test analyzes 161 genes associated with cancer to identify specific genetic mutations, copy number variations, and fusions that may be driving the cancer.
This test is often recommended for individuals diagnosed with cancer, especially when considering targeted therapies, or those with a strong family history of cancer.
The test requires a formalin-fixed paraffin-embedded (FFPE) tissue block, typically obtained from a biopsy or surgery. Ensure the block has at least 10% tumor tissue.
Results are generally available within 35 working days from the time the sample is received by the laboratory. Confirm with the laboratory before booking.
Results are typically provided to the ordering physician. It is important to discuss the results and their implications with your doctor or a genetic counselor.
Insurance coverage varies. Please check with your insurance provider regarding coverage for this specific test.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp